The role of DNA polymerase activity in human non-homologous end joining.
In mammalian cells, DNA double-strand breaks are repaired mainly by non-homologous end joining, which modifies and ligates two DNA ends without requiring extensive base pairing interactions for alignment. We investigated the role of DNA polymerases in DNA-PK-dependent end joining of restriction-digested plasmids in vitro and in vivo. Rejoining of DNA blunt ends as well as those with partially complementary 5' or 3' overhangs was stimulated by 20-53% in HeLa cell-free extracts when dNTPs were included, indicating that part of the end joining is dependent on DNA synthesis. This DNA synthesis-dependent end joining was sensitive to aphidicolin, an inhibitor of alpha-like DNA polymerases. Furthermore, antibodies that neutralize the activity of DNA polymerase alpha were found to strongly inhibit end joining in vitro, whereas neutralizing antibodies directed against DNA polymerases beta and epsilon did not. DNA sequence analysis of end joining products revealed two prominent modes of repair, one of which appeared to be dependent on DNA synthesis. Identical products of end joining were recovered from HeLa cells after transfection with one of the model substrates, suggesting that the same end joining mechanisms also operate in vivo. Fractionation of cell extracts to separate PCNA as well as depletion of cell extracts for PCNA resulted in a moderate but significant reduction in end joining activity, suggesting a potential role in a minor repair pathway.
Pospiech
H
H
Biocenter Oulu and Department of Biochemistry, PO Box 3000, FIN-90014 University of Oulu, Finland.
Rytkönen
A K
AK
Syväoja
J E
JE
D000906:Antibodies / Q000276:immunology / Q000494:pharmacology; D016590:Aphidicolin / Q000494:pharmacology; D001483:Base Sequence; D015139:Blotting, Southern; D002457:Cell Extracts; D004247:DNA / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism*; D004249:DNA Damage / Q000235:genetics; D004256:DNA Polymerase I / Q000037:antagonists & inhibitors / Q000276:immunology / Q000378:metabolism*; D004260:DNA Repair / Q000187:drug effects / Q000235:genetics*; D004261:DNA Replication / Q000187:drug effects / Q000235:genetics*; D051747:DNA-Activated Protein Kinase; D004268:DNA-Binding Proteins; D006367:HeLa Cells; D006801:Humans; D009687:Nuclear Proteins; D009711:Nucleotides / Q000378:metabolism; D010957:Plasmids / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism; D018809:Proliferating Cell Nuclear Antigen / Q000378:metabolism; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism; D011995:Recombination, Genetic / Q000187:drug effects / Q000235:genetics*; D017385:Sequence Homology; D013379:Substrate Specificity; D014162:Transfection
D000906:Antibodies; D002457:Cell Extracts; D004268:DNA-Binding Proteins; D009687:Nuclear Proteins; D009711:Nucleotides; D018809:Proliferating Cell Nuclear Antigen; D016590:Aphidicolin; D004247:DNA; D051747:DNA-Activated Protein Kinase; C497263:PRKDC protein, human; D017346:Protein Serine-Threonine Kinases; D004256:DNA Polymerase I